The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo.

Trial Profile

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2013

At a glance

  • Drugs TD 1414 (Primary)
  • Indications Bacterial infections; Impetigo; Wound infections
  • Focus Pharmacokinetics
  • Sponsors LEO Pharma
  • Most Recent Events

    • 14 Aug 2009 Actual patient number (20) added as reported by ClinicalTrials.gov.
    • 14 Aug 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Aug 2009 Actual initiation date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top